These Analysts Boost Their Forecasts On Edwards Lifesciences Following Q4 Results
Portfolio Pulse from Avi Kapoor
Edwards Lifesciences Corporation (NYSE:EW) reported Q4 earnings in line with expectations at 64 cents per share and sales of $1.53 billion, surpassing estimates. The company anticipates FY24 adjusted earnings of $2.70 to $2.80 per share on revenue of $6.6 billion. Following the report, Mizuho and RBC Capital raised their price targets on EW, with shares falling 1% to $87.40.
February 07, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences reported Q4 earnings in line with expectations and better-than-expected sales, with optimistic FY24 earnings and revenue outlook. Mizuho and RBC Capital raised their price targets.
The positive earnings report and optimistic future outlook, combined with the raised price targets from Mizuho and RBC Capital, indicate a potential for stock appreciation. However, the immediate 1% drop in share price suggests a mixed short-term reaction, possibly due to market expectations being already priced in.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100